Breast Cancer Anti-Estrogen Resistance Protein 3 (BCAR3) Antibody

Este producto es parte de BCAR scaffold protein, Cas family member
Product Graph
416€ (200 µl)

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.

935106861
info@markelab.com
name
Breast Cancer Anti-Estrogen Resistance Protein 3 (BCAR3) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx432398
tested applications
P-ELISA, WB

Description

BCAR3 Antibody is a Goat Polyclonal antibody against BCAR3.

Documents del producto

Instrucciones
Data sheet
Descargar

Product specifications

Category
Primary Antibodies
Immunogen Target
Breast Cancer Anti-Estrogen Resistance Protein 3 (BCAR3)
Host
Goat
Reactivity
Mouse
Recommended Dilution
P-ELISA: 1/32000. Optimal dilutions/concentrations should be determined by the end user.
Clonality
Polyclonal
Conjugation
Unconjugated
Isotype
IgG
Purification
Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.
Size 1
200 µl
Form
Liquid
Tested Applications
P-ELISA, WB
Buffer
Tris saline, pH 7.3, containing 0.02% sodium azide and 0.5% bovine serum albumin.
Availability
Shipped within 5-10 working days.
Storage
Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
Dry Ice
No
Gene ID
8412
NCBI Accession
NP_003558.1
Alias
BCAR3, NSP2, SH2D3B, breast cancer anti-estrogen resistance 3, AND-34, NSP family adaptor protein, BCAR3 adaptor protein, NSP family member, MIG7
Background
Antibody anti-BCAR3
Status
RUO
Note
Concentration: 0.5 mg/ml - 

Descripción

BCAR3, also known as Breast Cancer Anti-Estrogen Resistance Protein 3, is involved in the development of resistance to anti-estrogen therapies in breast cancer, much like its family members BCAR1 and BCAR2. BCAR3 has been shown to participate in signaling pathways that affect cell survival and migration. This protein is often implicated in the progression of cancer cells from an estrogen-dependent to an estrogen-independent state, allowing them to proliferate and survive despite the presence of estrogen inhibitors. BCAR3’s interaction with other molecular players in cell signaling, such as those controlling cytoskeletal reorganization, further contributes to cancer cell invasion and metastasis. Targeting BCAR3 may offer new therapeutic approaches for overcoming resistance in estrogen receptor-positive breast cancer, providing more effective treatments for patients with advanced disease. Its role in cancer progression and therapy resistance makes BCAR3 an important subject of ongoing research in oncology.

Related Products

abx129227

Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) Antibody

Breast Cancer Anti-Estrogen Resistance 3 Antibody is a Rabbit Polyclonal against Breast Cancer Anti-Estrogen Resistance 3.

Ver Producto
abx150793

Human Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) ELISA Kit

Human Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) ELISA Kit is an ELISA Kit for the in vitro quantitative measurement of Human Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) concentrations in serum, plasma, tissue homogenates and other biological fluids. This assay has high sensitivity and excellent specificity for detection of Breast Cancer Anti-Estrogen Resistance 3 (BCAR3)

Ver Producto
abx168253

Human Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) Protein

Breast Cancer Anti-Estrogen Resistance 3 Protein is a recombinant Human protein expressed in E. coli.

Ver Producto